Jazz Pharmaceuticals PLC (JAZZ)

139.21 +0.23  +0.17% NASDAQ Sep 22, 20:00 USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
11/05/2020 16:30 EST Misc Jazz Pharmaceuticals PLC Third Quarter Earnings Conference Call for 2020
11/05/2020 Earnings Jazz Pharmaceuticals PLC Third Quarter Earnings for 2020 Release
08/04/2020 16:30 EDT Misc Jazz Pharmaceuticals PLC Second Quarter Earnings Conference Call for 2020
08/04/2020 Earnings Jazz Pharmaceuticals PLC Second Quarter Earnings Result for 2020
07/30/2020 Misc Jazz Pharmaceuticals PLC Annual General Meeting for 2019
05/05/2020 16:30 EDT Misc Jazz Pharmaceuticals PLC First Quarter Earnings Conference Call for 2020
05/05/2020 Earnings Jazz Pharmaceuticals PLC First Quarter Earnings Result for 2020
02/25/2020 16:30 EST Misc Jazz Pharmaceuticals PLC Fourth Quarter Earnings Conference Call for 2019
02/25/2020 Earnings Jazz Pharmaceuticals PLC Fourth Quarter Earnings in 2019 Release
02/25/2020 Misc Jazz Pharmaceuticals PLC Annual Report for 2019
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.jazzpharmaceuticals.com
  • Investor Relations URL: http://investor.jazzpharma.com/phoenix.zhtml?c=210227&p=irol-irhome
  • HQ State/Province: N/A
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Value
  • Next Earnings Release: Nov. 05, 2020
  • Last Earnings Release: Aug. 04, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and indications in neuroscience and hematology-oncology. Jazz's product portfolio includes its lead drug, Xyrem, for narcolepsy, Sunosi for improving wakefulness in patients with excessive daytime sleepiness, Defitelio for severe veno-occlusive disease after stem cell transplant, Vyxeos for acute myeloid leukemia, and Zepzelca for small cell lung cancer.

Top Fund Holders

Symbol Name Weighting
XPH SPDR® S&P Pharmaceuticals ETF 4.46%
PPH VanEck Vectors Pharmaceutical ETF 3.85%
IHE iShares US Pharmaceuticals ETF 3.14%
PJP Invesco Dynamic Pharmaceuticals ETF 3.09%
RBF1542 RBC U.S. Mid-Cap Value Equity Fund D 2.35%
HNTVX Heartland Value Institutional 1.69%
FMPTX Fidelity Advisor® Mid Cap Value M 1.52%
FXH First Trust Health Care AlphaDEX® ETF 1.44%
HRMVX Harbor Mid Cap Value Admin 1.29%
TSMVX Transamerica Small/Mid Cap Value I2 1.19%
IBB iShares Nasdaq Biotechnology ETF 0.82%
MSCGX Mercer US Small/Mid Cap Equity Y3 0.60%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.